Cipepofol drug 5 mark answer for anaesthesia exam
Reading File
Finding Sources
Searching the Web
Cipepofol ciprofol anaesthesia drug mechanism dose uses
Searching PubMed
ciprofol anesthesia
Good, I have enough to write a solid exam answer. Not in the textbook library (it's a newer drug, HSK3486, approved ~2020-2022 in China), so I'll synthesize from PubMed reviews and web sources.
Cipepofol (Ciprofol / HSK3486) - 5 Mark Answer
Introduction
Cipepofol (INN/USAN), also known as ciprofol or by its developmental code HSK3486 (brand name Cypsedo), is a novel short-acting intravenous general anaesthetic and sedative agent, structurally a phenol derivative closely related to propofol.
Mechanism of Action
- Acts as a highly selective GABA-A receptor positive allosteric modulator, enhancing chloride ion influx and neuronal hyperpolarization, producing sedation/hypnosis (same broad mechanism as propofol).
- Structural modification (addition of a cyclopropyl group) increases receptor binding affinity, making it 4-6 times more potent than propofol on a mg/kg basis.
Pharmacokinetics
- Rapid onset and rapid offset, similar to propofol, due to high lipid solubility and fast redistribution/clearance.
- Administered by intravenous infusion (bolus for induction, continuous infusion for maintenance).
Dosing
- Induction: 0.4 mg/kg (range 0.3-0.5 mg/kg) IV - equivalent to propofol 2.0-2.5 mg/kg.
- Elderly (≥65 years): lower dose of 0.3 mg/kg recommended.
- Maintenance: initial infusion ~0.8-0.9 mg/kg/h, titrated to effect (roughly equivalent potency to isoflurane 5.7 mg/kg/h in one comparative study).
Clinical Uses
- Induction and maintenance of general anaesthesia in adults undergoing surgery.
- Procedural sedation for endoscopy (bronchoscopy, EGD, colonoscopy).
- Used successfully in gynaecological surgery, kidney transplantation, and cardiac surgery with cardiopulmonary bypass.
Advantages over Propofol
- Significantly less injection pain (due to reduced free phenol content in the formulation).
- More stable haemodynamics - smaller drop in blood pressure after induction.
- Comparable respiratory and cardiovascular depression profile to propofol, with possibly less pronounced hypotension/bradycardia.
- Similar rapid, clear-headed recovery profile (Quality of Recovery scores comparable/good).
Adverse Effects
- Similar side-effect profile to propofol: hypotension, bradycardia, apnoea/respiratory depression, injection site discomfort (though less than propofol).
Summary Table for exam
| Feature | Cipepofol (Ciprofol) |
|---|---|
| Class | GABA-A agonist, phenol derivative (propofol analog) |
| Potency vs propofol | 4-6x more potent |
| Induction dose | 0.4 mg/kg IV |
| Onset/offset | Rapid, similar to propofol |
| Key advantage | Less injection pain, stable haemodynamics |
| Route | IV only |
Note: This is a relatively new drug (approved in China ~2020-2022, code name HSK3486) not yet covered in most standard anaesthesia textbooks, so this answer is compiled from recent peer-reviewed reviews (PMID 36714027, 38589912, 38707079) and current pharmacology sources rather than a classical textbook citation.
This is a shared conversation. Sign in to Orris to start your own chat.